生物技术企业Korro Bio, Inc.最新财务数据显示,截至2026年3月31日,公司持有的现金、现金等价物及市场化证券总规模达到1.571亿美元。这一资金储备将为公司推进基因药物研发管线提供重要财务支撑。
生物技术企业Korro Bio, Inc.最新财务数据显示,截至2026年3月31日,公司持有的现金、现金等价物及市场化证券总规模达到1.571亿美元。这一资金储备将为公司推进基因药物研发管线提供重要财务支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.